A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer. The study shows that a combination of ...

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...

There are several pan-PIM kinase inhibitors in development for cancer indications, but startup Mysthera Therapeutics AG hopes to become the first biotech company to develop them in the autoimmune ...

Combining multiple kinase inhibitors may present off-target risks or unbalanced inhibition among different targets, that may be solved using rationally designed small molecules. Researchers from ...

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

Eilean Therapeutics LLC is a privately held biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small-molecule therapies that target genetic and ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...